Metformin & Glucagon: A Technical Pros and Cons Analysis
Abstract: This analysis evaluates metformin and glucagon within the peptide product landscape. Metformin offers proven glycemic control with low hypoglycemia risk but lacks direct GLP-1 agonism. Glucagon provides acute rescue therapy but has limited chronic utility. Current market trends favor dual-action peptides (e.g., tirzepatide) over monotherapies. Brand comparisons (e.g., Ozempic vs. Mounjaro) highlight superior weight loss and HbA1c reduction with multi-agonists. Technical pros include enhanced efficacy; cons involve gastrointestinal side effects and cost. Product parameters (purity >98%, stability at 2-8°C) and factory GMP certifications are critical for quality. Logistics require cold-chain compliance. Industry data projects 15% CAGR for peptide therapeutics, driven by obesity and diabetes applications. Selection criteria prioritize clinical data, regulatory approvals (FDA/EMA), and supply chain integrity.